Results 91 to 100 of about 766 (168)

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Tagraxofusp in combination with pomalidomide and dexamethasone in relapsed and / or refractory multiple myeloma shows encouraging preliminary efficacy with a manageable safety profile

Haematologica
Not available.
Paul Richardson, Myo Htut, Emma Scott, Claudia Paba Prada, Ira Gupta   +4 more
doaj   +1 more source

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies

, 2019
The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin ...
Testa, Castelli, Pelosi
core   +1 more source

Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database

Therapeutic Advances in Drug Safety
Background: The use of antineoplastic agents is one of the important triggers of tumor lysis syndrome (TLS), but there is still a lack of comprehensive understanding of antineoplastic agents that may trigger TLS and the TLS risk differences between ...
Dongxuan Li, Chunmeng Qin, Hongli Wang, Dan Du, Yalan Wang, Qian Du, Songqing Liu   +6 more
doaj   +1 more source

Response to Comment on: “First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level”

Haematologica
Not available.
Naveen Pemmaraju, Andrew A. Lane
doaj   +1 more source

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm

Blood Journal
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan, aggressive hematologic malignancy characterized by high CD123 expression. Tagraxofusp (TAG), a CD123-directed toxin, is the only approved therapy. Prior studies demonstrated BPDCN dependence on BCL2, sensitivity to venetoclax (VEN), and reversal of TAG resistance with azacitidine (AZA).
Andrew A. Lane, Marlise R. Luskin, Julia H. Keating, Nicole R. LeBoeuf, Jacqueline S. Garcia, Shai Shimony, Rebecca Leonard, Adon Goodpaster, Theresa Nguyen, Ilene Galinsky, Ashleigh Eberly Puleo, Naval G Daver, Nitin Jain, Guillermo Garcia-Manero, Hagop M Kantarjian, Marina Konopleva, Anthony S. Stein, Naveen Pemmaraju   +17 more
openaire   +1 more source

A Multidisciplinary Approach to Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Practical Recommendations and Insights from Countries of the Gulf Cooperation Council

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive orphan hematopoietic malignancy characterized by cutaneous and systemic hematologic involvement.
Ayman Al Hejazi, Phyu P. Aung, Nasir Bakshi, Robert S. Ohgami, Haitham Khogeer, Hatim Al-Maghraby, Ahmad S. Alotaibi, Rania Medhat Seliem, Heba Raslan, Areej Al Mugairi, Ramesh Pandita   +10 more
core   +1 more source

NEOPLASIA DE CÉLULAS DENDRÍTICAS PLASMOCITOIDES BLÁSTICAS EM PACIENTE JOVEM: RELATO DE CASO E REVISÃO DA LITERATURA

Hematology, Transfusion and Cell Therapy
Objetivo: Relatar o caso de uma paciente jovem com neoplasia de células dendríticas plasmocitoides blásticas (BPDCN), neoplasia hematológica rara e agressiva, destacando os desafios diagnósticos e o sucesso terapêutico após quimioterapia intensiva ...
Julia RISTOW DE ASSUNÇÃO, Camila BEZERRA ARRUDA LEDA, Gabriel VINÍCIUS DE OLIVEIRA ALVES, Gilberto DE FREITAS COLLI, Karolline GONÇALVES FERNANDES, Iara ZAPPAROLI GONÇALVES, Isabela ASSIS DE SIQUEIRA, Isabelle ADJANI SANTOS PLENTZ, Rafael GERAGE ROCHELLE, Raíssa HELLEN PRATES SILVEIRA   +9 more
doaj   +1 more source

NEOPLASIA DE CÉLULAS DENDRÍTICAS PLASMOCITOIDES BLÁSTICAS COM APRESENTAÇÃO LEUCÊMICA: UM RELATO DE CASO

Hematology, Transfusion and Cell Therapy
Introdução: A neoplasia de células dendríticas plasmocitoides blásticas (NCDPB) é um subtipo raro de malignidade de células dendríticas, correspondendo a cerca de 0,44% de todas as neoplasias hematológicas.
ACK Torrani, DH Catelli, FM Carlotto, JB Gazabon, MPMS Klauberg, RH Sassi, NH Dias, PA Guazzelli, MPB Malcon, AA Paz   +9 more
doaj   +1 more source

Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia

Blood Advances
Abstract CD123, a subunit of the interleukin-3 receptor, is expressed on ∼80% of acute myeloid leukemias (AMLs). Tagraxofusp (TAG), recombinant interleukin-3 fused to a truncated diphtheria toxin payload, is a first-in-class drug targeting CD123 approved for treatment of blastic plasmacytoid dendritic cell neoplasm.
Andrew A. Lane, Jacqueline S. Garcia, Evangeline G. Raulston, Jada L. Garzon, Ilene Galinsky, Emilie W. Baxter, Rebecca Leonard, Daniel J. DeAngelo, Marlise R. Luskin, Christopher R. Reilly, Maximilian Stahl, Richard M. Stone, Rahul S. Vedula, Martha M. Wadleigh, Eric S. Winer, Tariq Mughal, Christopher Brooks, Ira V. Gupta, Kristen E. Stevenson, Donna S. Neuberg, Siyang Ren, Julia Keating, Marina Konopleva, Anthony Stein, Naveen Pemmaraju   +24 more
openaire   +2 more sources